Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
The webcast will cover topline findings from the Phase 2 SANRECO trial of divesiran in polycythemia vera, a rare blood disorder.
- Silence Therapeutics held a conference call and webcast on Monday, August 10, 2026, to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera.
- Leveraging its mRNAi GOLD platform, the company develops novel siRNA therapies designed to target genes causing rare and common diseases with high unmet needs.
- Chairman and Interim Principal Executive Officer Iain Ross and Chief R&D Officer Steve Romano reviewed the study, while Chief Financial Officer Rhonda Helmes joined VP Gem Hopkins to address investor questions.
- Management explicitly noted that remarks regarding clinical development plans constitute forward-looking statements protected under the Private Securities Litigation Reform Act of 1995.
- The company's growing pipeline targets areas of high unmet need across rare and common diseases where existing treatments remain limited or inadequate.
18 Articles
18 Articles
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III.
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera August 10, 2026 8:00 AM EDTCompany...
Silence Therapeutics Polycythemia Vera Candidate Evaluated Against Takeda as AbCellera Shares Reach 2023 High
Market analysts are evaluating the potential of Silence Therapeutics’ polycythemia vera treatment, while the United Kingdom government has reaffirmed its commitment to childhood vaccination programs. In other industry developments, the Food and Drug Administration (FDA) issued a complete response letter for a radiopharmaceutical candidate, and AbCellera shares reached their highest valuation since 2023. Industry observers
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
